Genovese_Kremer_Mar2017

More documents

Recommendations

Info

Methods – Endpoints • The primary efficacy endpoint was the proportion of patients who achieved an ACR20 response at Week 12 • Secondary endpoints included: – Proportion achieving ACR50 and ACR70 – Proportion achieving DAS28(CRP) 3.2 or
Results – Baseline Demographics and Disease Activity (Study 1) Patient characteristic Placebo n=50 3 mg BID n=50 6 mg BID n=50 ABT-494 12 mg BID n=50 18 mg BID n=50 24 mg QD n=49 Age, mean (SD), years 55 (12) 53 (12) 55 (12) 56 (12) 55 (14) 56 (12) Female, n (%) 38 (76) 40 (80) 34 (68) 41 (82) 42 (84) 42 (86) RA duration, mean (SD), years 5.9 (5.3) 3.9 (3.8) 7.0 (5.5) 9.3 (8.6) 7.3 (7.9) 8.3 (7.1) Previous non-MTX DMARDs, n (%) 7 (14) 6 (12) 12 (24) 11 (22) 5 (10) 12 (24) HAQ-DI score, mean (SD) 1.4 (0.7) 1.3 (0.7) 1.6 (0.7) 1.5 (0.6) 1.6 (0.6) 1.5 (0.7) DAS28(CRP), mean (SD) 5.6 (1.1) 5.5 (1.1) 5.8 (1.0) 5.6 (0.9) 5.7 (0.8) 5.7 (1.0) CDAI score, mean (SD) 40 (14) 38 (13) 43 (14) 39 (12) 40 (13) 41 (13) hsCRP >ULN*, n (%) 27 (54) 25 (50) 31 (62) 26 (52) 28 (56) 33 (67) hsCRP, high-sensitivity C-reactive peptide; ULN, upper limit of normal (ULN=5 mg/L). <strong>Genovese</strong> MC, et al. Arthritis Rheum 2016;68:2857–66.
Page 1 and 2: Phase 2b Studies of ABT-494, a Sele
Page 3 and 4: Background and Objectives • ABT-4
Page 5: Methods - Study Design • These we
Page 9 and 10: Results - Primary Endpoint MTX inad
Page 11 and 12: Response rate (%) Response rate (%)
Page 13 and 14: Results - Safety Data Through Week
Page 15: Conclusions • Selective JAK-1 inh

Genovese_Kremer_Mar2017

Create successful ePaper yourself

Delete template?

Save as template?